Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.47 |
| ▸ | CTSK | P43235 | 13/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644981 | 0.90 | CTSS (0.44) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL21945571 | 0.90 | CTSS (0.44) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL29529201 | 0.84 | CTSS (0.45) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL21639080 | 0.82 | PTPN1 (0.50) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL21639081 | 0.82 | PTPN1 (0.50) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL29529139 | 0.81 | CTSS (0.44) | CTSSCTSKCTSLCTSB | |
| SCHEMBL19720149 | 0.78 | CTSS (0.46) | CTSSCTSKCTSLCTSB | |
| SCHEMBL18920552 | 0.77 | CTSS (0.58) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL16935712 | 0.77 | CTSS (0.58) | CTSSCTSKCTSLCTSBPTPN1 | |
| SCHEMBL2617261 | 0.77 | CTSS (0.58) | CTSSCTSKCTSLCTSBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3055298-B1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-10442789-B2 | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use | SUTRO BIOPHARMA, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180086734-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | SUTRO BIOPHARMA, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442789-B2 | Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use | DNPEP, SLC1A5, AADAT | CTSS 2493/4885CTSK 2069/4885CTSL 1316/4885 |
| US-20180086734-A1 | MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE | DNPEP, SLC1A5, AADAT | CTSS 2493/4885CTSK 2069/4885CTSL 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.